{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:53:56Z","timestamp":1791366836937,"version":"4.3.1"},"reference-count":110,"publisher":"Bentham Science Publishers Ltd.","issue":"16","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>This study aims to systematically synthesize current knowledge on the molecular\nand microenvironmental mechanisms driving sarcoma drug resistance, and to evaluate emerging precision\nstrategies for overcoming these obstacles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a comprehensive literature review (PubMed, Web of Science, Embase; inception\u2013\n31 July 2025) using MeSH and free-text terms relating to sarcoma, drug resistance, biomarkers, and precision\nmedicine. Inclusion criteria were peer-reviewed original or review studies in human or pre-clinical sarcoma\nmodels reporting resistance mechanisms or counter-strategies. Data were qualitatively categorized by\nresistance pathways (efflux pumps, DNA repair, apoptosis inhibition, secondary mutations, and immune\nevasion) and linked to therapeutic countermeasures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>ABC transporter over-expression (especially P-gp) and heightened DNA repair via homologous\nrecombination were recurrent chemo-resistance drivers. Targeted-therapy failure was dominated by secondary\nKIT\/PDGFRA or NTRK mutations, bypass signaling (PI3K\/AKT \u2194 RAS\/MAPK), and epithelial\u2013\nmesenchymal transition. Immune escape occurred through antigen loss, MHC-I down-regulation, adenosine-\nrich immunosuppressive microenvironments, and T-cell exhaustion (PD-1\/CTLA-4 up-regulation). Epigenetic\ndysregulation (EZH2, HDAC, DNMT) further fostered stem-like survival. Liquid-biopsy ctDNA\nenabled real-time resistance monitoring. Next-generation TKIs, dual-pathway inhibitors, epigenetic drugs,\nand rationally designed chemo-immuno combinations showed synergistic activity in pre-clinical and early\nclinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Integrating multi-omics profiling, liquid biopsies, and patient-derived organoids into adaptive\ntrial designs can individualize therapy sequences and delay resistance. Limitations include heterogeneous\nsarcoma biology, limited clinical validation, and economic barriers to the implementation of precision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Resistance to drugs in sarcoma is multifactorial and changeable. Nevertheless, fusing mechanistic\nknowledge with biomarker - guided combination\/sequential therapies offers a clear way to improve\npatient situations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0118715206435280260122110804","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:57:58Z","timestamp":1774022278000},"page":"1534-1552","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding Sarcoma Drug Resistance: From Molecular Mechanisms to Precision Interventions"],"prefix":"10.2174","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9284-7318","authenticated-orcid":true,"given":"Guizhen","family":"Lyu","sequence":"first","affiliation":[{"name":"Dongguan Key Laboratory of Clinical Medical Test Diagnostic Technology for Oncology, Dongguan Labway Clinical LaboratoryCo., Ltd., Dongguan, 523429, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5227-9643","authenticated-orcid":true,"given":"Dongbing","family":"Li","sequence":"additional","affiliation":[{"name":"Molecular Genetics Laboratory, Suzhou SANO Precision Medicine Co., Ltd., Suzhou, 215128, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e11131","DOI":"10.15252\/emmm.201911131","volume":"12","author":"Gr\u00fcnewald T.G.P.","year":"2020","unstructured":"Gr\u00fcnewald T.G.P.; Alonso M.; Avnet S.; Banito A.; Burdach S.; Cidre-Aranaz F.; Di Pompo G.; Distel M.; Dorado-Garcia H.; Garcia-Castro J.; Gonz\u00e1lez-Gonz\u00e1lez L.; Grigoriadis A.E.; Kasan M.; Koelsche C.; Krumbholz M.; Lecanda F.; Lemma S.; Longo D.L.; Madrigal-Esquivel C.; Morales-Molina \u00c1.; Musa J.; Ohmura S.; Ory B.; Pereira-Silva M.; Perut F.; Rodriguez R.; Seeling C.; Al Shaaili N.; Shaabani S.; Shiavone K.; Sinha S.; Tomazou E.M.; Trautmann M.; Vela M.; Versleijen-Jonkers Y.M.H.; Visgauss J.; Zalacain M.; Schober S.J.; Lissat A.; English W.R.; Baldini N.; Heymann D.; Sarcoma treatment in the era of molecular medicine. EMBO Mol Med  2020,12(11),e11131","journal-title":"EMBO Mol Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cancers17010010","volume":"17","author":"Mavroeidis L.","year":"2024","unstructured":"Mavroeidis L.; Napolitano A.; Huang P.; Jones R.L.; Novel therapeutics in soft tissue sarcoma. Cancers  2024,17(1),10","journal-title":"Cancers"},{"key":"ref=3","doi-asserted-by":"publisher","DOI":"10.2174\/0115665232417037250916112841","volume":"25","author":"Patel A.K.","year":"2025","unstructured":"Patel A.K.; Singh N.; Sachan N.; Chandra P.; Advancing Antibacterial Strategies: CRISPR-Phage-mediated gene therapy targeting bacterial resistance genes. Curr Gene Ther  2025,25","journal-title":"Curr Gene Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"100407","DOI":"10.1016\/j.iotech.2023.100407","volume":"20","author":"Anastasiou M.","year":"2023","unstructured":"Anastasiou M.; Kyriazoglou A.; Kotsantis I.; Economopoulou P.; Kyrkasiadou M.; Giannopoulou A.; Kosmidou A.; Smerdi D.; Moutafi M.; Gavrielatou N.; Psyrri A.; Immune checkpoint inhibitors in sarcomas: A systematic review. Immuno-Oncol Technol  2023,20,100407","journal-title":"Immuno-Oncol Technol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3390\/cancers14030548","volume":"14","author":"Ko A.","year":"2022","unstructured":"Ko A.; Coward V.S.; Gokgoz N.; Dickson B.C.; Tsoi K.; Wunder J.S.; Andrulis I.L.; Investigating the potential of isolating and expanding tumour-infiltrating lymphocytes from adult sarcoma. Cancers  2022,14(3),548","journal-title":"Cancers"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.20517\/cdr.2021.130","volume":"5","author":"Jubelin C.","year":"2022","unstructured":"Jubelin C.; Mu\u00f1oz-Garcia J.; Cochonneau D.; Moranton E.; Heymann M.F.; Heymann D.; Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma. Cancer Drug Resist  2022,5(1),184-198","journal-title":"Cancer Drug Resist"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s12672-024-01693-8","volume":"15","author":"Weijie S.","year":"2024","unstructured":"Weijie S.; Annexin A2: The feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment. DiscOncology  2024,15(1),783","journal-title":"DiscOncology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"e36839","DOI":"10.1016\/j.heliyon.2024.e36839","volume":"10","author":"Shao Y.","year":"2024","unstructured":"Shao Y.; Han S.; Hou Z.; Yang C.; Zhao Y.; Tumor-associated macrophages within the immunological milieu: An emerging focal point for therapeutic intervention. Heliyon  2024,10(17),e36839","journal-title":"Heliyon"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.19746\/j.cnki.issn.1009-2137.2023.02.041","volume":"31","author":"Zhang P.P.","year":"2023","unstructured":"Zhang P.P.; Li B.Z.; Geng Y.H.; Zhang F.; Yang Y.L.; Research progress on the role of tumor-associated macrophages in multiple myeloma --review. Zhongguo Shi Yan Xue Ye Xue Za Zhi  2023,31(2),589-592","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1158\/0008-5472.CAN-20-1344","volume":"80","author":"Nguyen F.","year":"2020","unstructured":"Nguyen F.; Guan P.; Guerrero D.T.; Kolla V.; Naraparaju K.; Perry L.M.; Soberman D.; Pressly B.B.; Alferiev I.S.; Chorny M.; Brodeur G.M.; Structural optimization and enhanced prodrug-mediated delivery overcomes camptothecin resistance in high-risk solid tumors. Cancer Res  2020,80(19),4258-4265","journal-title":"Cancer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.21873\/cdp.10313","volume":"4","author":"Kyriazoglou A.","year":"2024","unstructured":"Kyriazoglou A.; Moutafi M.; Zografos E.; Konteles V.; Sofianidis G.; Mahaira L.; Papakosta A.; Tourkantoni N.; Patereli A.; Stefanaki K.; Tzotzola V.; Mpaka M.; Polychronopoulou S.; Dimitriadis E.; Kattamis A.; Expression of DNA repair genes in ewing sarcoma. Cancer Diagn Progn  2024,4(3),231-238","journal-title":"Cancer Diagn Progn"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1053\/j.seminoncol.2020.10.002","volume":"47","author":"Oza J.","year":"2020","unstructured":"Oza J.; Doshi S.D.; Hao L.; Musi E.; Schwartz G.K.; Ingham M.; Homologous recombination repair deficiency as a therapeutic target in sarcoma. Semin Oncol  2020,47(6),380-389","journal-title":"Semin Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e16863","DOI":"10.15252\/emmm.202216863","volume":"15","author":"Planas-Paz L.","year":"2023","unstructured":"Planas-Paz L.; Pliego-Mendieta A.; Hagedorn C.; Aguilera-Garcia D.; Haberecker M.; Arnold F.; Herzog M.; Bankel L.; Guggenberger R.; Steiner S.; Chen Y.; Kahraman A.; Zoche M.; Rubin M.A.; Moch H.; Britschgi C.; Pauli C.; Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. EMBO Mol Med  2023,15(4),e16863","journal-title":"EMBO Mol Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/2767-9764.CRC-21-0047","volume":"2","author":"Maurer L.M.","year":"2022","unstructured":"Maurer L.M.; Daley J.D.; Mukherjee E.; Venier R.E.; Julian C.M.; Bailey N.G.; Jacobs M.F.; Kumar-Sinha C.; Raphael H.; Periyapatna N.; Weiss K.; Janeway K.A.; Mody R.; Lucas P.C.; McAllister-Lucas L.M.; Bailey K.M.; BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma. Cancer Res Commun  2022,2(4),220-232","journal-title":"Cancer Res Commun"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1158\/1078-0432.CCR-23-1531","volume":"30","author":"Laroche-Clary A.","year":"2024","unstructured":"Laroche-Clary A.; Josensi C.; Derieppe M.A.; Belhomme S.; Vendrely V.; Perret R.; Cadogan E.; Italiano A.; Selective DNA-PK inhibition enhances chemotherapy and ionizing radiation activity in soft-tissue sarcomas. selective DNA-PK inhibition enhances chemotherapy and ionizing radiation activity in soft-tissue sarcomas. Clin Cancer Res  2024,30(3),629-637","journal-title":"Clin Cancer Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1158\/1078-0432.CCR-23-3720","volume":"30","author":"Lee H.H.Y.","year":"2024","unstructured":"Lee H.H.Y.; Chow K.L.; Wong H.S.; Chong T.Y.; Wong A.S.T.; Cheng G.H.W.; Ko J.M.K.; Siu H.C.; Yeung M.C.F.; Huen M.S.Y.; Tse K.Y.; Bray M.R.; Mak T.W.; Leung S.Y.; Ip P.P.C.; Inhibition of aberrantly overexpressed polo-like kinase 4 is a potential effective treatment for dna damage repair-deficient uterine leiomyosarcoma. Clin Cancer Res  2024,30(17),3904-3918","journal-title":"Clin Cancer Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41419-020-02910-2","volume":"11","author":"Muenchow A.","year":"2020","unstructured":"Muenchow A.; Weller S.; Hinterleitner C.; Malenke E.; Bugl S.; Wirths S.; M\u00fcller M.R.; Schulze-Osthoff K.; Aulitzky W.E.; Kopp H.G.; Essmann F.; The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA Cell Death Dis  2020,11(8),701","journal-title":"a concerted mechanism requiring BAX and NOXA Cell Death Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"e70770","DOI":"10.1002\/cam4.70770","volume":"14","author":"Kawaguchi S.","year":"2025","unstructured":"Kawaguchi S.; Nishisho T.; Toki S.; Takeuchi M.; Tamaki S.; Sairyo K.; Blue light emitting diode suppresses sarcoma cell proliferation via the endogenous apoptotic pathway without damaging normal cells. Cancer Med  2025,14(6),e70770","journal-title":"Cancer Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1634413","DOI":"10.3389\/fphar.2025.1634413","volume":"16","author":"Chen F.","year":"2025","unstructured":"Chen F.; Fu Y.; Bai G.; Qiu J.; Hua K.; Multi-omics dissection of tumor microenvironment-mediated drug resistance: Mechanisms and therapeutic reprogramming. Front Pharmacol  2025,16,1634413","journal-title":"Front Pharmacol"},{"key":"ref=20","first-page":"267","volume":"28","author":"Florou V.","year":"2019","unstructured":"Florou V.; Trent J.C.; Wilky B.A.; Precision medicine in gastrointestinal stromal tumors. Discov Med  2019,28(155),267-276","journal-title":"Discov Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"eaaz2481","DOI":"10.1126\/scitranslmed.aaz2481","volume":"12","author":"Banks E.","year":"2020","unstructured":"Banks E.; Grondine M.; Bhavsar D.; Barry E.; Kettle J.G.; Reddy V.P.; Brown C.; Wang H.; Mettetal J.T.; Collins T.; Adeyemi O.; Overman R.; Lawson D.; Harmer A.R.; Reimer C.; Drew L.; Packer M.J.; Cosulich S.; Jones R.D.O.; Shao W.; Wilson D.; Guichard S.; Fawell S.; Anjum R.; Discovery and pharmacological characterization of AZD3229, a potent KIT\/PDGFR\u03b1 inhibitor for treatment of gastrointestinal stromal tumors. Sci Transl Med  2020,12(541),eaaz2481","journal-title":"Sci Transl Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.3390\/cancers13112541","volume":"13","author":"Addeo A.","year":"2021","unstructured":"Addeo A.; Banna G.L.; Friedlaender A.; KRAS G12C mutations in NSCLC: From target to resistance. Cancers  2021,13(11),2541","journal-title":"Cancers"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1394702","DOI":"10.3389\/fonc.2024.1394702","volume":"14","author":"Lokhandwala J.","year":"2024","unstructured":"Lokhandwala J.; Smalley T.B.; Tran T.H.; Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance. Front Oncol  2024,14,1394702","journal-title":"Front Oncol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12967-023-04063-0","volume":"21","author":"Zhao Y.","year":"2023","unstructured":"Zhao Y.; Weng Z.; Zhou X.; Xu Z.; Cao B.; Wang B.; Li J.; Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-\u03b22 J Transl Med  2023,21(1),219","journal-title":"by activating the PI3K-AKT pathway via TGF-\u03b22 J Transl Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13046-021-02048-9","volume":"40","author":"Jimenez-Garc\u00eda M.P.","year":"2021","unstructured":"Jimenez-Garc\u00eda M.P.; Lucena-Cacace A.; Otero-Albiol D.; Carnero A.; Empty spiracles homeobox genes EMX1 and EMX2 regulate WNT pathway activation in sarcomagenesis. J Exp Clin Cancer Res  2021,40(1),247","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673343892241207034138","volume":"32","author":"Beylerli O.","year":"2025","unstructured":"Beylerli O.; Musaev E.; Soto G.R.; Rangel C.C.; De Jesus Encarnacion Ramirez M.; Ilyasova T.; Interaction between microRNA and KRAS in glioblastoma. Curr Med Chem  2025,32","journal-title":"Curr Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/cells10051154","volume":"10","author":"Pacini L.","year":"2021","unstructured":"Pacini L.; Jenks A.D.; Lima N.C.; Huang P.H.; Targeting the fibroblast growth factor receptor (FGFR) family in lung cancer. Cells  2021,10(5),1154","journal-title":"Cells"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"106945","DOI":"10.1016\/j.phrs.2023.106945","volume":"197","author":"Lin C.P.","year":"2023","unstructured":"Lin C.P.; Wu S.H.; Lin T.Y.; Chu C.H.; Lo L.W.; Kuo C.C.; Chang J.Y.; Hsu S.C.; Ko B.S.; Yao M.; Hsiao J.K.; Wang S.W.; Huang D.M.; Lysosomal-targeted doxorubicin delivery using RBC-derived vesicles to overcome drug-resistant cancer through mitochondrial-dependent cell death. Pharmacol Res  2023,197,106945","journal-title":"Pharmacol Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/2159-8290.CD-23-0110","volume":"14","author":"Kazansky Y.","year":"2024","unstructured":"Kazansky Y.; Cameron D.; Mueller H.S.; Demarest P.; Zaffaroni N.; Arrighetti N.; Zuco V.; Kuwahara Y.; Somwar R.; Ladanyi M.;; Qu, R.; de Stanchina, E.; Dela Cruz, F.S.; Kung, A.L.; Gounder, M.M.; Kentsis, A. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. Overcoming clinical resistance to ezh2 inhibition using rational epigenetic combination therapy. Cancer Discov  2024,14(6),965-981","journal-title":"Cancer Discov"},{"key":"ref=30","doi-asserted-by":"publisher","unstructured":"Hernandez, K.C.; Shah, A.M.; Lopez, V.A.; Tagliabracci, V.S.;  Chen, K.; Xu, L.; Bassel-Duby, R.; Olson, E.N.; Liu, N. CD73 contributes to the pathogenesis of fusion-negative rhabdomyosarcoma through the purinergic signaling pathway. Proc. Natl. Acad. Sci. USA, 2024, 121(4), e2315925121.","DOI":"10.1073\/pnas.2315925121"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"151889","DOI":"10.1016\/j.anndiagpath.2021.151889","volume":"57","author":"Bell D.","year":"2022","unstructured":"Bell D.; Phan J.; DeMonte F.; Hanna E.Y.; High-grade transformation of low-grade biphenotypic sinonasal sarcoma: Radiological, morphophenotypic variation and confirmatory molecular analysis. Ann Diagn Pathol  2022,57,151889","journal-title":"Ann Diagn Pathol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1111\/cas.15915","volume":"114","author":"Hirose T.","year":"2023","unstructured":"Hirose T.; Ikegami M.; Kojima S.; Yoshida A.; Endo M.; Shimada E.; Kanahori M.; Oyama R.; Matsumoto Y.; Nakashima Y.; Kawai A.; Mano H.; Kohsaka S.; Extensive analysis of 59 sarcoma-related fusion genes identified pazopanib as a potential inhibitor to COL1A1-PDGFB fusion gene. Cancer Sci  2023,114(10),4089-4100","journal-title":"Cancer Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/1541-7786.MCR-22-0544","volume":"21","author":"Kamens J.L.","year":"2023","unstructured":"Kamens J.L.; Dang J.; Shaw T.I.; Gout A.M.; Newman S.; Hagiwara K.; Smith A.M.R.; Obermayer A.N.; Aldridge S.; Ma J.; Zhang Y.; Wu G.; Leventaki V.; Santiago T.; Raimondi S.; Nakitandwe J.; Pappo A.; Li C.; Zhang J.; Gruber T.A.; Malignant progression of an ancestral bone marrow clone harboring a CIC-NUTM2A fusion in isolated myeloid sarcoma. Mol Cancer Res  2023,21(4),301-306","journal-title":"Mol Cancer Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"115381","DOI":"10.1016\/j.celrep.2025.115381","volume":"44","author":"Noorizadeh R.","year":"2025","unstructured":"Noorizadeh R.; Sax B.; Javaheri T.; Radic-Sarikas B.; Fock V.; Suresh V.; Kauer M.; Bykov A.; Kurija D.; Schlederer M.; Kenner L.; Weber G.; Mikulits W.; Halbritter F.; Moriggl R.; Kovar H.; YAP1 is a key regulator of EWS:FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cells. Cell Rep  2025,44(3),115381","journal-title":"Cell Rep"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s00262-024-03822-2","volume":"73","author":"Renne S.L.","year":"2024","unstructured":"Renne S.L.; Sama' L.; Kumar S.; Mintemur O.; Ruspi L.; Santori I.; Sicoli F.; Bertuzzi A.; Laffi A.; Bonometti A.; Colombo P.; D'amato V.; Bressan A.; Scorsetti M.; Terracciano L.; Navarria P.; D'incalci M.; Quagliuolo V.; Pasqualini F.; Grizzi F.; Cananzi F.C.M.; Disruptions in antigen processing and presentation machinery on sarcoma. Cancer Immunol Immunother  2024,73(11),228","journal-title":"Cancer Immunol Immunother"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e006930","DOI":"10.1136\/jitc-2023-006930","volume":"11","author":"Frankiw L.","year":"2023","unstructured":"Frankiw L.; Singh A.; Peters C.; Comin-Anduix B.; Berent-Maoz B.; Macabali M.; Shammaie K.; Quiros C.; Kaplan-Lefko P.; Baselga Carretero I.; Ribas A.; Nowicki T.S.; Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade. J Immunother Cancer  2023,11(5),e006930","journal-title":"J Immunother Cancer"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1265469","DOI":"10.3389\/fimmu.2023.1265469","volume":"14","author":"Lim W.C.","year":"2024","unstructured":"Lim W.C.; Marques Da Costa M.E.; Godefroy K.; Jacquet E.; Gragert L.; Rondof W.; Marchais A.; Nhiri N.; Dalfovo D.; Viard M.; Labaied N.; Khan A.M.; Dessen P.; Romanel A.; Pasqualini C.; Schleiermacher G.; Carrington M.; Zitvogel L.; Scoazec J.Y.; Geoerger B.; Salmon J.; Divergent HLA variations and heterogeneous expression but recurrent HLA loss-ofheterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers. Front Immunol  2024,14,1265469","journal-title":"Front Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1396187","DOI":"10.3389\/fimmu.2024.1396187","volume":"15","author":"Bauer M.","year":"2024","unstructured":"Bauer M.; Monecke A.; Hackl H.; Wilfer A.; Jaekel N.; Bl\u00e4ker H.; Al-Ali H.K.; Seliger B.; Wickenhauser C.; Association of immune evasion in myeloid sarcomas with disease manifestation and patients' survival. Front Immunol  2024,15,1396187","journal-title":"Front Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1026135","DOI":"10.3389\/fphar.2023.1026135","volume":"14","author":"Qi W.","year":"2023","unstructured":"Qi W.; Xi D.; Bai Y.; Liu L.; Ma Y.; Yin Z.; Chen H.; Case report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. Front Pharmacol  2023,14,1026135","journal-title":"Front Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3390\/biomedicines9121798","volume":"9","author":"Fleuren E.D.G.","year":"2021","unstructured":"Fleuren E.D.G.; Terry R.L.; Meyran D.; Omer N.; Trapani J.A.; Haber M.; Neeson P.J.; Ekert P.G.; Enhancing the potential of immunotherapy in paediatric sarcomas: Breaking the immunosuppressive barrier with receptor tyrosine kinase inhibitors. Biomedicines  2021,9(12),1798","journal-title":"Biomedicines"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/2767-9764.CRC-23-0027","volume":"3","author":"Visser L.L.","year":"2023","unstructured":"Visser L.L.; Bleijs M.; Margaritis, T.; van de Wetering, M.; Holstege, F.C.P.; Clevers, H. Ewing sarcoma single-cell transcriptome analysis reveals functionally impaired antigen-presenting cells. Cancer Res Commun  2023,3(10),2158-2169","journal-title":"Cancer Res Commun"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"12209","DOI":"10.3390\/ijms252212209","volume":"25","author":"Cruz-Ramos M.","year":"2024","unstructured":"Cruz-Ramos M.; Cabrera-Nieto S.A.; Murguia-Perez M.; Fajardo-Espinoza F.S.; The role of adenosine in overcoming resistance in sarcomas. Int J Mol Sci  2024,25(22),12209","journal-title":"Int J Mol Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1187289","DOI":"10.3389\/fendo.2023.1187289","volume":"14","author":"Weil R.","year":"2023","unstructured":"Weil R.; Loeb D.; Breaking down the tumor immune infiltration within pediatric sarcomas. Front Endocrinol  2023,14,1187289","journal-title":"Front Endocrinol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-024-02020-y","volume":"23","author":"He F.","year":"2025","unstructured":"He F.; Xu J.; Zeng F.; Wang B.; Yang Y.; Xu J.; Sun X.; Ren T.; Tang X.; Integrative analysis of Ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy. Cell Commun Signal  2025,23(1),23","journal-title":"Cell Commun Signal"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"961021","DOI":"10.3389\/fcell.2022.961021","volume":"10","author":"Clutton G.T.","year":"2022","unstructured":"Clutton G.T.; Weideman A.M.K.; Goonetilleke N.P.; Maurer T.; An expanded population of CD8dim T cells with features of mitochondrial dysfunction and senescence is associated with persistent HIV-associated Kaposi's sarcoma under ART Front Cell Dev Biol  2022,10,961021","journal-title":"persistent HIV-associated Kaposi's sarcoma under ART Front Cell Dev Biol"},{"key":"ref=46","doi-asserted-by":"publisher","author":"Pan H.","unstructured":"Pan H.; Liu Y.; Fuller A.M.; Williams E.F.; Fraietta J.A.; Eisinger T.S.K.; Collagen modification remodels the sarcoma tumor microenvironment and promotes resistance to immune checkpoint inhibition. bioRxiv, 2024: 2024-06.","DOI":"10.1101\/2024.06.28.601055"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"678127","DOI":"10.3389\/fcell.2021.678127","volume":"9","author":"Kinker G.S.","year":"2021","unstructured":"Kinker G.S.; Vitiello G.A.F.; Ferreira W.A.S.; Chaves A.S.; Cordeiro de Lima, V.C.; Medina, T.S. B cell orchestration of anti-tumor immune responses: A matter of cell localization and communication. Front Cell Dev Biol  2021,9,678127","journal-title":"Front Cell Dev Biol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/1078155220938849","volume":"27","author":"Goh X.N.","year":"2021","unstructured":"Goh X.N.; Seng M.S.F.; Loh A.H.P.; Gupta A.; Chang K.T.E.; Iyer P.; Larotrectinib followed by selitrectinib in a novel DCTN1-NTRK1 fusion undifferentiated pleomorphic sarcoma. J Oncol Pharm Pract  2021,27(2),485-489","journal-title":"J Oncol Pharm Pract"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/diagnostics11030478","volume":"11","author":"Siozopoulou V.","year":"2021","unstructured":"Siozopoulou V.; Smits E.; De Winne K.; Marcq E.; Pauwels P.; NTRK fusions in sarcomas: Diagnostic challenges and clinical aspects. Diagnostics  2021,11(3),478","journal-title":"Diagnostics"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2174\/0113895575270904231129062137","volume":"24","author":"Wani A.K.","year":"2024","unstructured":"Wani A.K.; Singh R.; Akhtar N.; Prakash A.; Nepovimova E.; Oleksak P.; Chrienova Z.; Alomar S.; Chopra C.; Kuca K.; Targeted inhibition of the PI3K\/Akt\/mTOR signaling axis: Potential for sarcoma therapy. Mini Rev Med Chem  2024,24(16),1496-1520","journal-title":"Mini Rev Med Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"10732748211038424","DOI":"10.1177\/10732748211038424","volume":"28","author":"Yuan J.","year":"2021","unstructured":"Yuan J.; Li X.; Yu S.; Molecular targeted therapy for advanced or metastatic soft tissue sarcoma. Cancer Contr  2021,28,10732748211038424","journal-title":"Cancer Contr"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.3390\/ijms23073540","volume":"23","author":"Nakano K.","year":"2022","unstructured":"Nakano K.; Challenges of systemic therapy investigations for bone sarcomas. Int J Mol Sci  2022,23(7),3540","journal-title":"Int J Mol Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1080\/14656566.2023.2224500","volume":"24","author":"Meissner M.","year":"2023","unstructured":"Meissner M.; Napolitano A.; Thway K.; Huang P.; Jones R.L.; Pharmacotherapeutic strategies for epithelioid sarcoma: Are we any closer to a non-surgical cure? Expert Opin Pharmacother  2023,24(12),1395-1401","journal-title":"Expert Opin Pharmacother"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.3760\/cma.j.cn112137-20220112-00077","volume":"102","author":"Fan L.","year":"2022","unstructured":"Fan L.; Ye T.; Chen, J. (Current status and prospects of anti-angiogenic small-molecule tyrosine kinase inhibitors in the therapy of soft tissue sarcoma). Zhonghua Yi Xue Za Zhi  2022,102(31),2405-2410","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","volume":"323","author":"Tap WD","year":"2020","unstructured":"Tap WD; Wagner AJ; Sch\u00f6ffski P; Martin-Broto J; Krarup-Hansen A; Ganjoo KN; Yen CC; Abdul Razak AR; Spira A; Kawai A; Le Cesne A.; Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial. Jama  2020,323(13),1266-76","journal-title":"Jama"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.3390\/ijerph20136288","volume":"20","author":"Asfa S.","year":"2023","unstructured":"Asfa S.; Toy H.I.; Arshinchi Bonab R.; Chrousos G.P.; Pavlopoulou A.; Geronikolou S.A.; Soft tissue ewing sarcoma cell drug resistance revisited: A systems biology approach. Int J Environ Res Public Health  2023,20(13),6288","journal-title":"Int J Environ Res Public Health"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.21873\/anticanres.17202","volume":"44","author":"Morinaga S.","year":"2024","unstructured":"Morinaga S.; Han Q.; Mizuta K.; Kang B.M.; Sato M.; Bouvet M.; Yamamoto N.; Hayashi K.; Kimura H.; Miwa S.; Igarashi K.; Higuchi T.; Tsuchiya H.; Demura S.; Hoffman R.M.; Recombinant methioninase increases eribulin efficacy 16-fold in highly eribulin-resistant HT1080 fibrosarcoma cells, demonstrating potential to overcome the clinical challenge of drug-resistant soft-tissue sarcoma. Anticancer Res  2024,44(9),3777-3783","journal-title":"Anticancer Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/CCO.0000000000001149","volume":"37","author":"Martin-Broto J.","year":"2025","unstructured":"Martin-Broto J.; Moura D.S.; Hindi N.; Which sarcoma requires PD1\/PDL1 inhibitors, and what should be the best scheme? Present status and next steps. Curr Opin Oncol  2025,37(4),331-338","journal-title":"Curr Opin Oncol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1159\/000526018","volume":"15","author":"Saijo K.","year":"2022","unstructured":"Saijo K.; Imai H.; Katayama H.; Fujishima F.; Nakamura K.; Kasahara Y.; Ouchi K.; Komine K.; Shirota H.; Takahashi M.; Ishioka C.; BRAF and MEK inhibitor treatment for metastatic undifferentiated sarcoma of the spermatic cord with BRAF V600E mutation. Case Rep Oncol  2022,15(2),762-769","journal-title":"Case Rep Oncol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/CCO.0000000000001048","volume":"36","author":"Strauss S.J.","year":"2024","unstructured":"Strauss S.J.; Berlanga P.; McCabe M.G.; Emerging therapies in ewing sarcoma. Curr Opin Oncol  2024,36(4),297-304","journal-title":"Curr Opin Oncol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/jjco\/hyab005","volume":"51","author":"Nakata E.","year":"2021","unstructured":"Nakata E.; Fujiwara T.; Kunisada T.; Ito T.; Takihira S.; Ozaki T.; Immunotherapy for sarcomas. Jpn J Clin Oncol  2021,51(4),523-537","journal-title":"Jpn J Clin Oncol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.soc.2022.03.004","volume":"31","author":"Moreno Tellez C.","year":"2022","unstructured":"Moreno Tellez C.; Leyfman Y.; D'Angelo S.P.; Wilky, B.A.; Dufresne, A Immunotherapy in Sarcoma Surg Oncol Clin N Am  2022,31(3),381-397","journal-title":"Dufresne, A Immunotherapy in Sarcoma Surg Oncol Clin N Am"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1150765","DOI":"10.3389\/fonc.2023.1150765","volume":"13","author":"Seong G.","year":"2023","unstructured":"Seong G.; D'Angelo S.P.; New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas. Front Oncol  2023,13,1150765","journal-title":"Front Oncol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3390\/biomedicines10030573","volume":"10","author":"Kerrison W.G.J.","year":"2022","unstructured":"Kerrison W.G.J.; Lee A.T.J.; Thway K.; Jones R.L.; Huang P.H.; Current status and future directions of immunotherapies in soft tissue sarcomas. Biomedicines  2022,10(3),573","journal-title":"Biomedicines"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3390\/cancers13030363","volume":"13","author":"Koumarianou A.","year":"2021","unstructured":"Koumarianou A.; Duran-Moreno J.; The sarcoma immune landscape: Emerging challenges, prognostic significance and prospective impact for immunotherapy approaches. Cancers  2021,13(3),363","journal-title":"Cancers"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1095219","DOI":"10.3389\/fonc.2023.1095219","volume":"13","author":"Merlini A.","year":"2023","unstructured":"Merlini A.; Pavese V.; Manessi G.; Rabino M.; Tolomeo F.; Aliberti S.; D'Ambrosio L.; Grignani G.; Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions. Front Oncol  2023,13,1095219","journal-title":"Front Oncol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1292325","DOI":"10.3389\/fimmu.2024.1292325","volume":"15","author":"Liao Z.","year":"2024","unstructured":"Liao Z.; Teng J.; Li T.; Liu H.; Li T.; Zhang C.; Xing R.; Teng S.; Yang Y.; Zhao J.; Xiao W.; Zhang G.; Li M.J.; Yao W.; Yang J.; Evaluation of the efficacy and safety of immunotherapy in sarcoma: A two-center study. Front Immunol  2024,15,1292325","journal-title":"Front Immunol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3390\/curroncol30020165","volume":"30","author":"Gingrich A.A.","year":"2023","unstructured":"Gingrich A.A.; Nassif E.F.; Roland C.L.; Keung E.Z.; The landscape of immunotherapy for retroperitoneal sarcoma. Curr Oncol  2023,30(2),2144-2158","journal-title":"Curr Oncol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"493","DOI":"10.18632\/oncotarget.28606","volume":"15","author":"Sinichenkova K.","year":"2024","unstructured":"Sinichenkova K.; Sidorov I.; Kriventsova N.; Konovalov D.; Abasov R.; Usman N.; Karachunskiy A.; Novichkova G.; Litvinov D.; Druy A.; Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors. Oncotarget  2024,15(1),493-500","journal-title":"Oncotarget"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1158\/0008-5472.CAN-22-2258","volume":"83","author":"Nguyen T.D.T.","year":"2023","unstructured":"Nguyen T.D.T.; Wang Y.; Bui T.N.; Lazcano R.; Ingram D.R.; Yi M.; Vakulabharanam V.; Luo L.; Pina M.A.; Karakas C.; Li M.; Kettner N.M.; Somaiah N.; Hougton P.J.; Mawlawi O.; Lazar A.J.; Hunt K.K.; Keyomarsi K.; Sequential targeting of retinoblastoma and dna synthesis pathways is a therapeutic strategy for sarcomas that can be monitored in real time. Cancer Res  2023,83(6),939-955","journal-title":"Cancer Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"101689","DOI":"10.1016\/j.adro.2024.101689","volume":"10","author":"Burner D.N.","year":"2025","unstructured":"Burner D.N.; Hendrickson P.G.; Cardona D.M.; Blazer D.G.; Mullins J.B.; Kirsch D.G.; Response to central boost radiation therapy in unresectable retroperitoneal sarcoma: A case series. Adv Radiat Oncol  2025,10(2),101689","journal-title":"Adv Radiat Oncol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-3-030-96376-7_7","volume":"183","author":"Lu K.","year":"2022","unstructured":"Lu K.; Chiu K.Y.; Cheng C.L.; Immunotherapy in genitourinary malignancy: Evolution in revolution or revolution in evolution. Cancer Treat Res  2022,183,201-223","journal-title":"Cancer Treat Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s00120-020-01234-5","volume":"59","author":"Schmid S.C.","year":"2020","unstructured":"Schmid S.C.; Koll F.J.; Beckert F.; Seitz A.K.; Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer. Urologe A  2020,59(7),790-796","journal-title":"Urologe A"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2202085","DOI":"10.1002\/adhm.202202085","volume":"12","author":"Chen Y.","year":"2023","unstructured":"Chen Y.; Xiong T.; Zhao X.; Du J.; Sun W.; Fan J.; Peng X.; Tumor cell-responsive photodynamic immunoagent for immunogenicity-enhanced orthotopic and remote tumor therapy. Adv Healthc Mater  2023,12(5),2202085","journal-title":"Adv Healthc Mater"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3892\/ol.2022.13184","volume":"23","author":"Alzaaqi S.","year":"2022","unstructured":"Alzaaqi S.; Naka N.; Hamada K.; Hosen N.; Kanegae M.; Outani H.; Adachi M.; Imanishi R.; Morii E.; Iwai M.; Nakata J.; Fujiki F.; Morimoto S.; Nakajima H.; Nishida S.; Tsuboi A.; Oka Y.; Sugiyama H.; Oji Y.; WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine. Oncol Lett  2022,23(2),65","journal-title":"Oncol Lett"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3390\/cancers15082287","volume":"15","author":"Albarr\u00e1n V.","year":"2023","unstructured":"Albarr\u00e1n V.; Villamayor M.L.; Pozas J.; Chamorro J.; Rosero D.I.; San Rom\u00e1n M.; Guerrero P.; P\u00e9rez de Aguado, P.; Calvo, J.C.; Garc\u00eda de Quevedo, C.; Gonz\u00e1lez, C.; Vaz, M.\u00c1. Current landscape of immunotherapy for advanced sarcoma. Cancers  2023,15(8),2287","journal-title":"Cancers"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3390\/pharmaceutics15041143","volume":"15","author":"Said S.S.","year":"2023","unstructured":"Said S.S.; Ibrahim W.N.; Cancer resistance to immunotherapy: comprehensive insights with future perspectives. Pharmaceutics  2023,15(4),1143","journal-title":"Pharmaceutics"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"200822","DOI":"10.1016\/j.omton.2024.200822","volume":"32","author":"Robinson S.I.","year":"2024","unstructured":"Robinson S.I.; Rochell R.E.; Penza V.; Naik S.; Translation of oncolytic viruses in sarcoma. Mol Ther Oncol  2024,32(3),200822","journal-title":"Mol Ther Oncol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12951-025-03445-4","volume":"23","author":"Yang Y.","year":"2025","unstructured":"Yang Y.; Guo J.; Qi J.; Deng W.; Hu J.; Hasan M.W.; Deng F.; Zhou Y.; Song Z.; Deng W.; Chen W.; A lyophilizable LNP vaccine enables STING-reinforced postoperational adjuvant immunotherapy. J Nanobiotechnology  2025,23(1),379","journal-title":"J Nanobiotechnology"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1007\/s12325-020-01379-x","volume":"37","author":"Rugo H.S.","year":"2020","unstructured":"Rugo H.S.; Jacobs I.; Sharma S.; Scappaticci F.; Paul T.A.; Jensen-Pergakes K.; Malouf G.G.; The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: A narrative review. Adv Ther  2020,37(7),3059-3082","journal-title":"Adv Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2021.0270","volume":"19","author":"Lu J.","year":"2022","unstructured":"Lu J.; Li T.; Liao Z.; Yu H.; Zhao Y.; Wu H.; Ren Z.; Zhao J.; Xing R.; Teng S.; Yang Y.; Li X.; Chen K.; Trent J.; Yang J.; The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma. Cancer Biol Med  2022,19(6),1-21","journal-title":"Cancer Biol Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e002181","DOI":"10.1136\/jitc-2020-002181","volume":"9","author":"Simonds E.F.","year":"2021","unstructured":"Simonds E.F.; Lu E.D.; Badillo O.; Karimi S.; Liu E.V.; Tamaki W.; Rancan C.; Downey K.M.; Stultz J.; Sinha M.; McHenry L.K.; Nasholm N.M.; Chuntova P.; Sundstr\u00f6m A.; Genoud V.; Shahani S.A.; Wang L.D.; Brown C.E.; Walker P.R.; Swartling F.J.; Fong L.; Okada H.; Weiss W.A.; Hellstr\u00f6m M.; Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. J Immunother Cancer  2021,9(6),e002181","journal-title":"J Immunother Cancer"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/ijms25031643","volume":"25","author":"Hong Y.","year":"2024","unstructured":"Hong Y.; Zhang L.; Lin W.; Yang Y.; Cao Z.; Feng X.; Yu Z.; Gao Y.; Transcriptome sequencing unveils a molecular-stratification-predicting prognosis of sarcoma associated with lipid metabolism. Int J Mol Sci  2024,25(3),1643","journal-title":"Int J Mol Sci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3390\/ijms26051973","volume":"26","author":"Sias F.","year":"2025","unstructured":"Sias F.; Zoroddu S.; Migheli R.; Bagella L.; Untangling the role of myc in sarcomas and its potential as a promising therapeutic target. Int J Mol Sci  2025,26(5),1973","journal-title":"Int J Mol Sci"},{"key":"ref=85","doi-asserted-by":"publisher","author":"O'Donnell E.","unstructured":"O'Donnell E.; Mu\u00f1oz M.; Davis R.; Randall R.L.; Tepper C.; Carr-Ascher J.; Genetic and epigenetic characterization of sarcoma stem cells across subtypes identifies EZH2 as a therapeutic target. bioRxiv, 2025, 9(1): 7.","DOI":"10.1101\/2024.05.14.594060"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.3390\/jcm10122621","volume":"10","author":"Men\u00e9ndez S.T.","year":"2021","unstructured":"Men\u00e9ndez S.T.; Gallego B.; Murillo D.; Rodr\u00edguez A.; Rodr\u00edguez R.; Cancer stem cells as a source of drug resistance in bone sarcomas. J Clin Med  2021,10(12),2621","journal-title":"J Clin Med"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3390\/cells11081267","volume":"11","author":"Aryee D.N.T.","year":"2022","unstructured":"Aryee D.N.T.; Fock V.; Kapoor U.; Radic-Sarikas B.; Kovar H.; Zooming in on long non-coding rnas in ewing sarcoma pathogenesis. Cells  2022,11(8),1267","journal-title":"Cells"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1186\/s12885-021-08579-w","volume":"21","author":"Harttrampf A.C.","year":"2021","unstructured":"Harttrampf A.C.; da Costa M.E.M.; Renoult A.; Daudigeos-Dubus E.; Geoerger B.; Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation. BMC Cancer  2021,21(1),833","journal-title":"BMC Cancer"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/cancers16020271","volume":"16","author":"Lesovaya E.A.","year":"2024","unstructured":"Lesovaya E.A.; Fetisov T.I.; Bokhyan B.Y.; Maksimova V.P.; Kulikov E.P.; Belitsky G.A.; Kirsanov K.I.; Yakubovskaya M.G.; Genetic, epigenetic and transcriptome alterations in liposarcoma for target therapy selection. Cancers  2024,16(2),271","journal-title":"Cancers"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1002319","DOI":"10.37349\/etat.2025.1002319","volume":"6","author":"Chantre-Justino M.","year":"2025","unstructured":"Chantre-Justino M.; Meohas W.; The DNA methylation landscape of musculoskeletal sarcomas. Explor Target Anti-Tumor Ther  2025,6,1002319","journal-title":"Explor Target Anti-Tumor Ther"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/gcc.23142","volume":"62","author":"Tanaka M.","year":"2023","unstructured":"Tanaka M.; Nakamura T.; Targeting epigenetic aberrations of sarcoma in CRISPR era. Genes Chromosomes Cancer  2023,62(9),510-525","journal-title":"Genes Chromosomes Cancer"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"322","DOI":"10.21147\/j.issn.1000-9604.2024.03.08","volume":"36","author":"Fan Z.","year":"2024","unstructured":"Fan Z.; Dong S.; Wang N.; Khawar B.M.; Wang J.; Sun H.; Unlocking epigenetics for precision treatment of Ewing's sarcoma. Chin J Cancer Res  2024,36(2),322-340","journal-title":"Chin J Cancer Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cell.2020.03.042","volume":"181","author":"Rothbart S.B.","year":"2020","unstructured":"Rothbart S.B.; Baylin S.B.; Epigenetic therapy for epithelioid sarcoma. Cell  2020,181(2),211","journal-title":"Cell"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"e2100211","DOI":"10.1200\/PO.21.00211","volume":"6","author":"Hsu J.Y.","year":"2022","unstructured":"Hsu J.Y.; Seligson N.D.; Hays J.L.; Miles W.O.; Chen J.L.; Clinical utility of CDK4\/6 inhibitors in sarcoma: Successes and future challenges. JCO Precis Oncol  2022,6(6),e2100211","journal-title":"JCO Precis Oncol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"966","DOI":"10.26355\/eurrev_202202_28006","volume":"26","author":"Song X.J.","year":"2022","unstructured":"Song X.J.; Bi M.C.; Zhu Q.S.; Liu X.L.; The emerging role of lncRNAs in the regulation of osteosarcoma stem cells. Eur Rev Med Pharmacol Sci  2022,26(3),966-974","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"80","DOI":"10.31083\/j.fbl2902080","volume":"29","author":"Hu H.","year":"2024","unstructured":"Hu H.; Song H.; Han B.; Zhao H.; He J.; Tumor-educated platelet RNA and circulating free RNA: Emerging liquid biopsy markers for different tumor types. Front Biosci-Landmark  2024,29(2),80","journal-title":"Front Biosci-Landmark"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jsps.2021.12.009","volume":"30","author":"Abdel-Latif R.T.","year":"2022","unstructured":"Abdel-Latif R.T.; Wadie W.; Abdel-mottaleb Y.; Abdallah D.M.; El-Maraghy N.N.; El-Abhar H.S.; Reposition of the anti-inflammatory drug diacerein in an in-vivo colorectal cancer model. Saudi Pharm J  2022,30(1),72-90","journal-title":"Saudi Pharm J"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e2500228","DOI":"10.1200\/PO-25-00228","volume":"9","author":"Gupta K.","year":"2025","unstructured":"Gupta K.; Grimison P.; Fernandez K.; Choi V.; Bhadri V.; Real-world clinical utility of tumor next-generation sequencing in adolescent and young adult patients with sarcoma. Real-world clinical utility of tumor next-generation sequencing in adolescent and young adult patients with sarcoma. JCO Precis Oncol  2025,9(9),e2500228","journal-title":"JCO Precis Oncol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.3390\/cancers14081988","volume":"14","author":"Fayzullina D.","year":"2022","unstructured":"Fayzullina D.; Tsibulnikov S.; Stempen M.; Schroeder B.A.; Kumar N.; Kharwar R.K.; Acharya A.; Timashev P.; Ulasov I.; Novel targeted therapeutic strategies for ewing sarcoma. Cancers  2022,14(8),1988","journal-title":"Cancers"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1158\/1541-7786.MCR-20-0651","volume":"19","author":"Martin J.C.","year":"2021","unstructured":"Martin J.C.; Hoegel T.J.; Lynch M.L.; Woloszynska A.; Melendy T.; Ohm J.E.; Exploiting replication stress as a novel therapeutic intervention. Mol Cancer Res  2021,19(2),192-206","journal-title":"Mol Cancer Res"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/biom15071046","volume":"15","author":"Olvera-Valencia M.","year":"2025","unstructured":"Olvera-Valencia M.; Luna-Maldonado F.; Juarez-Reyes J.; Lopez-Saavedra A.; Coronel-Hernandez J.; Millan-Catalan O.; Guzman-Gomez D.; Rodr\u00edguez-Izquierdo F.; Herrera L.A.; Cant\u00fa-De Le\u00f3n D.F.; Perez-Plasencia C.; P\u00e9rez-Yepez E.A.; BUB1 an overexpressed kinase in sarcoma: Finding new target therapy for osteosarcoma, liposarcoma, synovial sarcoma, and leiomyosarcoma. Biomolecules  2025,15(7),1046","journal-title":"Biomolecules"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.3390\/cancers14153812","volume":"14","author":"Hai Y.","year":"2022","unstructured":"Hai Y.; Kawachi A.; He X.; Yoshimi A.; Pathogenic roles of RNA-Binding proteins in sarcomas. Cancers  2022,14(15),3812","journal-title":"Cancers"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00292-020-00759-y","volume":"41","author":"Haybaeck J.","year":"2020","unstructured":"Haybaeck J.; Roessner A.; Malignant round cell tumors. Pathologe  2020,41(2),116-122","journal-title":"Pathologe"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.3390\/jcm13216500","volume":"13","author":"Fuchs B.","year":"2024","unstructured":"Fuchs B.; Heesen P.; From data integration to precision medicine: A value-based healthcare approach for sarcoma care. J Clin Med  2024,13(21),6500","journal-title":"J Clin Med"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcancer.2023.07.003","volume":"95","author":"Meng Y.","year":"2023","unstructured":"Meng Y.; Yang Y.; Hu M.; Zhang Z.; Zhou X.; Artificial intelligence-based radiomics in bone tumors: Technical advances and clinical application. Semin Cancer Biol  2023,95,75-87","journal-title":"Semin Cancer Biol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"123546","DOI":"10.1016\/j.biomaterials.2025.123546","volume":"324","author":"Ma H.","year":"2026","unstructured":"Ma H.; Li X.; Li J.; Bu J.; Li X.; Zhang J.; Yu S.; Nie G.; Wang H.; Feng H.; Generation of patient-derived sarcoma organoids for personalized drug screening and precision cancer immunotherapy. Biomaterials  2026,324,123546","journal-title":"Biomaterials"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/13543784.2024.2414119","volume":"33","author":"Filippi L.","year":"2024","unstructured":"Filippi L.; Ferrari C.; Rubini G.; Theranostic strategies in sarcoma: Preliminary clinical evidence. Expert Opin Investig Drugs  2024,33(11),1119-1127","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.3390\/cancers15174339","volume":"15","author":"Xu S.","year":"2023","unstructured":"Xu S.; Tan S.; Guo L.; Patient-derived organoids as a promising tool for multimodal management of sarcomas. Cancers  2023,15(17),4339","journal-title":"Cancers"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/CCO.0000000000001143","volume":"37","author":"Lasalvia P.","year":"2025","unstructured":"Lasalvia P.; Lillini R.; Trama A.; Collecting information from all sarcoma reference cancer centres worldwide: Achievement and next steps. Curr Opin Oncol  2025,37(4),339-346","journal-title":"Curr Opin Oncol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.3390\/ijms26093937","volume":"26","author":"Khobragade S.S.","year":"2025","unstructured":"Khobragade S.S.; Deshmukh M.; Vyas U.; Ingle R.G.; Innovative approaches in bone tissue engineering: Strategies for cancer treatment and recovery. Int J Mol Sci  2025,26(9),3937","journal-title":"Int J Mol Sci"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715206435280260122110804","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/251091\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715206435280260122110804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:23:25Z","timestamp":1791365005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/251091\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":110,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0118715206435280260122110804","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}